The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss but was plagued by ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

At Reuters Pharma USA last month, Editor in Chief Jonah Comstock caught up with John Androsavich, general manager of Gingko ...

For example, if they are trained on data that reflects existing disparities in treatment or demographics, the AI could perpetuate these inequalities, leading to poorer patient outcomes. To guard ...